A Novel Murine Model of Pregnancy and Transfusion Induced Anti-Kell RBC Alloimmunization

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 715-715
Author(s):  
Nicole H. Smith ◽  
Kate Henry ◽  
James C. Zimring ◽  
Jeanne E. Hendrickson

Abstract Abstract 715 Introduction: Pregnancy and transfusion induced RBC alloimmunization can be clinically significant, leading to difficulties with future transfusions and also leading to hemolytic disease of the fetus and newborn (HDFN). Maternal anti-Kell alloimmunization is one of the most common causes of non ABO-mediated HDFN. To date, there are few treatments to prevent HDFN due to RBC antibodies outside of the Rh(D) family, and there are few existing animal models of pregnancy induced RBC alloimmunization. Herein, we describe a novel murine model in which Kell RBC alloimmunization occurs following pregnancy or transfusion. Materials and Methods: Mice with RBC specific expression of the K2 allele of the human Kell glycoprotein (subsequently referred to as “K2” mice) were generated utilizing constructs containing the human K2 sequence expressed by beta-globin regulatory elements. For the transfusion induced alloimmunization experiments, C57BL/6 female recipients were transfused 3 times with K2 RBCs in the presence of poly (I:C), with anti-Kell glycoprotein antibodies measured after each transfusion by flow cytometric crossmatch using K2 targets and subtype specific antibodies. For the pregnancy induced alloimmunization experiments, control naïve C57BL/6 females were mated with K2 males three times; females immunized following transfusion were mated with K2 males as well. After the final pregnancy, anti-Kell glycoprotein antibodies were also measured by flow cytometric. Number and percentage of K2 positive pups were noted in a subset of pregnancies, and deceased pups were genotyped by PCR. Results: Anti-Kell glycoprotein antibodies were detectable in C57BL/6 recipients following either K2 RBC transfusion or following repeat pregnancies with K2 positive fetuses. In 5 experiments, 30/30 transfused mice had anti-Kell antibody titers that increased with subsequent transfusion, with IgM, IgG1, IgG2b, IgG2c, and IgG3 anti-Kell being detectable. After 2–3 pregnancies with K2 mates, 11/12 C57BL/6 females developed anti-Kell glycoprotein antibodies, with IgM and all IgG anti-Kell subtypes being present. Regardless of the mechanism of immunization (e.g. transfusion or prior pregnancy), live births and pups surviving beyond day of life #2 were lower in Kell immunized mothers compared with control non-immunized mothers (approximately 2–4 pups compared to 6–10 pups). At least one K2 stillborn pup had severe edema resembling hydrops. Discussion: This is the first animal model of Kell RBC alloimmunization, in which anti-Kell can be generated either through prior pregnancy or transfusion and appears to be detrimental to pups. This model mimics that of pregnancy or transfusion induced anti-Rh(D), in that the described antigen (K2) is largely foreign to the C57BL/6 recipients (who lack human K1 or K2 altogether). Ongoing studies are investigating whether a particular method of immunization (e.g. pregnancy vs transfusion) is more detrimental to fetuses and pups. As expected, the anti-Kell antibody appears more detrimental to K2 positive than negative fetuses, with immunized mothers having smaller litters of predominantly K2 negative fetuses; however, K2 negative pups may also have higher rates of demise following birth to immunized compared to non-immunized mothers. In sum, this model will allow for further investigation of pregnancy and transfusion induced anti-Kell RBC alloimmunization, and may also serve to increase the understanding of the pathogenesis and prevention of HDFN. Disclosures: Zimring: Immucor: Funds from an Immucor sponsored project (unrelated to the current project) were utilized in part to generate the KEL transgenic animals.

1986 ◽  
Vol 6 (11) ◽  
pp. 3798-3806
Author(s):  
L E Babiss ◽  
J M Friedman ◽  
J E Darnell

In the accompanying paper (Friedman et al., Mol. Cell. Biol. 6:3791-3797, 1986), hepatoma-specific expression of the rat albumin promoter within the adenovirus genome was demonstrated. However, the rate of transcription was very low compared with that of the endogenous chromosomal albumin gene. Here we show that in hepatoma cells the adenovirus E1A enhancer, especially in the presence of E1A protein, greatly stimulates transcription from the albumin promoter but not the mouse beta-globin promoter. This enhancer-dependent stimulation did not occur in myeloma cells in which a virus containing a immunoglobulin promoter and enhancer did function. These experiments suggest a limited distribution in cultured differentiated cells of cell-specific transcription factors. However, either the regulation of such cell-specific factors breaks down in other cultured cells, or strictly cell-specific factors are not at play in controlling cell-specific transcription, because HeLa cells could transcribe the albumin promoter from the same start site about 10% as well as hepatomas could and 293 cells could transcribe both albumin and globin promoters.


1986 ◽  
Vol 6 (11) ◽  
pp. 3798-3806 ◽  
Author(s):  
L E Babiss ◽  
J M Friedman ◽  
J E Darnell

In the accompanying paper (Friedman et al., Mol. Cell. Biol. 6:3791-3797, 1986), hepatoma-specific expression of the rat albumin promoter within the adenovirus genome was demonstrated. However, the rate of transcription was very low compared with that of the endogenous chromosomal albumin gene. Here we show that in hepatoma cells the adenovirus E1A enhancer, especially in the presence of E1A protein, greatly stimulates transcription from the albumin promoter but not the mouse beta-globin promoter. This enhancer-dependent stimulation did not occur in myeloma cells in which a virus containing a immunoglobulin promoter and enhancer did function. These experiments suggest a limited distribution in cultured differentiated cells of cell-specific transcription factors. However, either the regulation of such cell-specific factors breaks down in other cultured cells, or strictly cell-specific factors are not at play in controlling cell-specific transcription, because HeLa cells could transcribe the albumin promoter from the same start site about 10% as well as hepatomas could and 293 cells could transcribe both albumin and globin promoters.


1999 ◽  
Vol 19 (2) ◽  
pp. 1558-1568 ◽  
Author(s):  
Ganesh Lakshmanan ◽  
Ken H. Lieuw ◽  
Kim-Chew Lim ◽  
Yi Gu ◽  
Frank Grosveld ◽  
...  

ABSTRACT We found previously that neither a 6-kbp promoter fragment nor even a 120-kbp yeast artificial chromosome (YAC) containing the whole GATA-3 gene was sufficient to recapitulate its full transcription pattern during embryonic development in transgenic mice. In an attempt to further identify tissue-specific regulatory elements modulating the dynamic embryonic pattern of the GATA-3 gene, we have examined the expression of two much larger (540- and 625-kbp) GATA-3 YACs in transgenic animals. A lacZ reporter gene was first inserted into both large GATA-3 YACs. The transgenic YAC patterns were then compared to those of embryos bearing the identical lacZinsertion in the chromosomal GATA-3 locus (creating GATA-3/lacZ “knock-ins”). We found that most of the YAC expression sites and tissues are directly reflective of the endogenous pattern, and detailed examination of the integrated YAC transgenes allowed the general localization of a number of very distant transcriptional regulatory elements (putative central nervous system-, endocardium-, and urogenital system-specific enhancers). Remarkably, even the 625-kbp GATA-3 YAC, containing approximately 450 kbp and 150 kbp of 5′ and 3′ flanking sequences, respectively, does not contain the full transcriptional regulatory potential of the endogenous locus and is clearly missing regulatory elements that confer tissue-specific expression to GATA-3 in a subset of neural crest-derived cell lineages.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 842-842 ◽  
Author(s):  
Jeanne E. Hendrickson ◽  
Nicole H. Smith ◽  
Kathryn R. Girard-Pierce ◽  
Christopher A Tormey ◽  
Kate L. Henry ◽  
...  

Abstract Abstract 842 Introduction: Aspects of RBC antigens that define their immunogenicity are not fully understood. Multiple studies in humans have demonstrated Rh(D) to be the most immunogenic RBC antigen, yet the same antigen present in lower copy number (weak Rh(D)) is, with rare exception, considered non-immunogenic. A better understanding of factors influencing RBC alloimmunogenicity would be helpful in predicting antibody responses in transfusion and pregnancy situations alike, as well as in managing donor RBC inventory. Herein, we describe the generation of transgenic mice with different levels of RBC specific expression of the clinically significant human KEL2 antigen, and test the hypothesis that antigen density impacts recipient immune response post-transfusion. Materials and Methods: Mice with RBC specific expression of KEL2 were generated utilizing constructs containing the human KEL2 sequence expressed behind a B-globin promoter, using a random integration approach. TER119+, CD45+, and CD41+ cells were evaluated by flow cytometry for KEL expression using monoclonal anti-Jsa and anti-Kpb, and RBC antigen density was estimated utilizing QIFIKIT beads. MuMT recipients were transfused with RBCs labeled with a lipophilic dye, and post-transfusion RBC recovery and antigen expression were evaluated by flow cytometry. To determine the immunogenicity of KEL2 or weak KEL2 RBCs, RBCs were transfused into C57BL/6 recipients every 2–3 weeks in the presence or absence of poly (I:C) pre-treatment. Recipient serum was analyzed by flow cytometric crossmatch with KEL2 or C57BL/6 RBC targets, using IgM or IgG secondary antibodies. To determine the effect of recipient RBC expression of weak KEL2 on the immunogenicity of KEL2 RBCs, weak KEL2 animals were transfused with KEL2 RBCs, the clearance of lipophilic labeled RBCs was tracked, and anti-KEL was evaluated on the transfused RBCs and also in the serum. Results: KEL2 RBCs have approximately 1200 antigenic sites per cell, whereas weak KEL2 RBCs have fewer than 200 sites; flow cytometric studies of TER 119+, CD45+, and CD41+ cells suggest both strains have RBC specific KEL expression. Transfusion of KEL2 or weak KEL2 RBCs into muMT animals resulted in stable post-transfusion RBC recovery and antigen expression. In 3/3 experiments (n=30 animals), all C57BL/6 recipients of KEL2 RBCs generated detectable anti-KEL IgM and IgG, which boosted with subsequent transfusions and which was enhanced in the presence of recipient inflammation with poly (I:C). However, in 2/2 experiments (n=20 animals), weak KEL RBCs led to no detectable antibody (IgM or IgG) in C57BL/6 recipients following 3 transfusions, even in the presence of recipient pre-treatment with poly (I:C). Furthermore, weak KEL2 recipients of KEL2 RBCs generated no detectable IgG and demonstrated no clearance of KEL2 RBCs, though low levels of anti-KEL IgM were detectable on the transfused RBCs and in the serum from approximately 5–12 days post-transfusion. Discussion: As hypothesized, antigen density significantly impacts the immunogenicity of KEL RBCs in this reductionist murine alloimmunization model. C57BL/6 recipients, like Rh(D) negative recipients, lack the human antigen in question (KEL2 in this case), and recipient antibody responses to weak KEL2 are, like most recipient responses to weak Rh(D), undetectable. Strengths of the KEL2 and weak KEL2 system include the fact that these animals are, to the best of our knowledge, genetically identical except for RBC KEL antigen copy number. Thus, this system allows for detailed analyses of the immune response to KEL RBCs with different antigen densities, on both the donor and recipient side of the equation, without confounding factors encountered in human studies (such as HLA presentation issues or considerations of the molecular basis of a particular type of weak Rh(D)). A better understanding of primary, secondary, and other immune responses in the KEL2 and weak KEL2 system may lay the groundwork for strategies to induce non-responsiveness to RBCs in humans, not only in the setting of transfusion medicine but also potentially in the setting of hemolytic disease of the fetus and newborn. Furthermore, translation of these and future findings in the KEL and weak KEL systems to Rh(D), weak Rh(D), and other human antigen systems may ultimately allow for creative solutions in blood inventory management. Disclosures: No relevant conflicts of interest to declare.


2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Juliana Bonin Ferreira ◽  
Zvonimir Poljak ◽  
Robert Friendship ◽  
Éva Nagy ◽  
Greg Wideman ◽  
...  

AbstractInfluenza A viruses (IAVs) are common causes of respiratory infection in pigs. The objective of this study was to characterize the circulation of IAVs between weaning and market age on the basis of development of antibody response and molecular epidemiology of detected viruses. Two batches of weaned pigs were followed in the nursery and finisher barns with a sample of 81 and 75 pigs. Nasal swabs and blood samples were collected from individual pigs for virological and serological analyses. A H3N2 subtype virus, of cluster IV, was detected in Study 1, with a maximum of 97.9% identity to HA gene of viruses previously isolated in Ontario. In Study 2, a H1N1 subtype virus, of 2009 H1N1 pandemic lineage, was detected, with a maximum of 97.8% identity to HA gene of viruses previously isolated in Ontario. On the basis of HA gene, it was observed that pigs were being detected with the same virus over time. The existence of antibody titers for IAV other than the isolated one confirmed that more than one subtype can circulate in the same population. In Study 1, pigs with higher numbers of IAV detection had lower serological titers for the same virus that was confirmed to circulate in the nursery (P < 0.01). Thorough knowledge of all endemic viral strains is fundamental for development of infection and disease control, particularly in complex production systems. This may include consideration of sampling and testing strategies which could detect circulation of all IAV variants, even if they have low prevalence.


Blood ◽  
1995 ◽  
Vol 85 (2) ◽  
pp. 319-329 ◽  
Author(s):  
S Dziennis ◽  
RA Van Etten ◽  
HL Pahl ◽  
DL Morris ◽  
TL Rothstein ◽  
...  

Abstract CD11b is the alpha chain of the Mac-1 integrin and is preferentially expressed in myeloid cells (neutrophils, monocytes, and macrophages). We have previously shown that the CD11b promoter directs cell-type- specific expression in myeloid lines using transient transfection assays. To confirm that these promoter sequences contain the proper regulatory elements for correct myeloid expression of CD11b in vivo, we have used the -1.7-kb human CD11b promoter to direct reporter gene expression in transgenic mice. Stable founder lines were generated with two different reporter genes, a Thy 1.1 surface marker and the Escherichia coli lacZ (beta-galactosidase) gene. Analysis of founders generated with each reporter demonstrated that the CD11b promoter was capable of driving high levels of transgene expression in murine macrophages for the lifetime of the animals. Similar to the endogenous gene, transgene expression was preferentially found in mature monocytes, macrophages, and neutrophils and not in myeloid precursors. These experiments indicate that the -1.7 CD11b promoter contains the regulatory elements sufficient for high-level macrophage expression. This promoter should be useful for targeting heterologous gene expression to mature myeloid cells.


1993 ◽  
Vol 13 (1) ◽  
pp. 9-17 ◽  
Author(s):  
J P Concordet ◽  
M Salminen ◽  
J Demignon ◽  
C Moch ◽  
P Maire ◽  
...  

The human aldolase A gene is transcribed from three different promoters, pN, pM, and pH, all of which are clustered within a small 1.6-kbp DNA domain. pM, which is highly specific to adult skeletal muscle, lies in between pN and pH, which are ubiquitous but particularly active in heart and skeletal muscle. A ubiquitous enhancer, located just upstream of pH start sites, is necessary for the activity of both pH and pN in transient transfection assays. Using transgenic mice, we studied the sequence controlling the muscle-specific promoter pM and the relations between the three promoters and the ubiquitous enhancer. A 4.3-kbp fragment containing the three promoters and the ubiquitous enhancer showed an expression pattern consistent with that known in humans. In addition, while pH was active in both fast and slow skeletal muscles, pM was active only in fast muscle. pM activity was unaltered by the deletion of a 1.8-kbp region containing the ubiquitous enhancer and the pH promoter, whereas pN remained active only in fast skeletal muscle. These findings suggest that in fast skeletal muscle, a tissue-specific enhancer was acting on both pN and pM, whereas in other tissues, the ubiquitous enhancer was necessary for pN activity. Finally, a 2.6-kbp region containing the ubiquitous enhancer and only the pH promoter was sufficient to bring about high-level expression of pH in cardiac and skeletal muscle. Thus, while pH and pM function independently of each other, pN, remarkably, shares regulatory elements with each of them, depending on the tissue. Importantly, expression of the transgenes was independent of the integration site, as originally described for transgenes containing the beta-globin locus control region.


Sign in / Sign up

Export Citation Format

Share Document